TScan Therapeutics, Inc. (TCRX)

NASDAQ: TCRX · IEX Real-Time Price · USD
2.79
-0.03 (-1.06%)
At close: Sep 27, 2022 10:47 AM
2.71
-0.08 (-2.87%)
After-hours: Sep 27, 2022 4:00 PM EDT
-1.06%
Market Cap 67.16M
Revenue (ttm) 12.34M
Net Income (ttm) -61.29M
Shares Out 24.07M
EPS (ttm) -3.28
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,259
Open 2.80
Previous Close 2.82
Day's Range 2.71 - 2.86
52-Week Range 1.60 - 9.35
Beta n/a
Analysts Buy
Price Target 14.28 (+411.8%)
Earnings Date Aug 18, 2022

About TCRX

TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a colla... [Read more...]

Industry Biotechnology
IPO Date Jul 16, 2021
Employees 115
Stock Exchange NASDAQ
Ticker Symbol TCRX
Full Company Profile

Financial Performance

In 2021, TCRX's revenue was $10.14 million, an increase of 834.65% compared to the previous year's $1.09 million. Losses were -$48.63 million, 86.1% more than in 2020.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for TCRX stock is "Buy." The 12-month stock price forecast is 14.28, which is an increase of 411.83% from the latest price.

Price Target
$14.28
(411.83% upside)
Analyst Consensus: Buy
Stock Forecasts

News

TScan Therapeutics to Participate in Upcoming Investor Conferences

WALTHAM, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T ce...

5 days ago - GlobeNewsWire

TScan Therapeutics Secures Convertible Debt Facility for up to $60 Million with K2 HealthVentures

Financing supports management's focus on clinical execution and advancing its ImmunoBank

2 weeks ago - GlobeNewsWire

TScan Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

WALTHAM, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T ce...

2 weeks ago - GlobeNewsWire

TScan Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Progress

Phase 1 umbrella trial for hematologic malignancies open for enrollment

1 month ago - GlobeNewsWire

TScan Therapeutics to Participate in the 13th Annual Wedbush PacGrow Healthcare Conference

WALTHAM, Mass., Aug. 03, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cel...

1 month ago - GlobeNewsWire

TScan Therapeutics Announces Publication in Cell Highlighting the Discovery of Tumor Antigens and TCRs for the Treatm...

TScan screening technology used to identify the targets of expanded T cell clones in the tumors of patients with head and neck cancer responding to neoadjuvant immunotherapy

2 months ago - GlobeNewsWire

TScan Therapeutics Appoints Debora Barton, M.D., as Chief Medical Officer

WALTHAM, Mass., July 07, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cel...

2 months ago - GlobeNewsWire

TScan Therapeutics to Participate in the LifeSci 2nd Annual Genetic Medicines Symposium

WALTHAM, Mass., June 22, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cel...

3 months ago - GlobeNewsWire

TScan Therapeutics to Participate in the 2022 Jefferies Healthcare Conference

WALTHAM, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cel...

3 months ago - GlobeNewsWire

TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-101 for the Treatment of H...

Study start-up activities now ongoing for all three arms of the Phase 1 umbrella trial of TSC-100 and TSC-101 Study start-up activities now ongoing for all three arms of the Phase 1 umbrella trial of TS...

3 months ago - GlobeNewsWire

TScan Therapeutics Presents Preclinical Data at the American Society of Gene and Cell Therapy 25th Annual Meeting

Identified lead TCR-T cell therapy candidate, TCR-200-A02, for the treatment of HPV-positive solid tumors, on track for IND submission in 2H22

4 months ago - GlobeNewsWire

TScan Therapeutics to Participate in the H.C. Wainwright Global Investment Conference

WALTHAM, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell...

4 months ago - GlobeNewsWire

TScan Therapeutics to Host Virtual KOL Event to Discuss its Solid Tumor Program Strategy and Highlights from the ASGC...

WALTHAM, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell...

4 months ago - GlobeNewsWire

TScan Therapeutics Reports First Quarter 2022 Financial Results and Upcoming Anticipated Milestones

Preclinical data to be presented at the American Society of Gene & Cell Therapy 25 th Annual Meeting; virtual KOL event following the conference

4 months ago - GlobeNewsWire

TScan Therapeutics Announces Upcoming Presentations at the 25th American Society of Gene and Cell Therapy Annual Meeting

Company to host a virtual KOL event to discuss highlights from the meeting on Thursday, May 19, 2022, at 4:30 p.m. ET Company to host a virtual KOL event to discuss highlights from the meeting on Thursd...

4 months ago - GlobeNewsWire

TScan Therapeutics Appoints Leiden Dworak, CPA, MBA, as Vice President, Finance

WALTHAM, Mass., April 11, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T ce...

5 months ago - GlobeNewsWire

TScan Therapeutics Reports Full Year 2021 Financial Results and Highlights Key 2022 Priorities

Received FDA clearance of IND for TSC-100 for the treatment of hematologic malignancies

6 months ago - GlobeNewsWire

TScan Therapeutics Announces Presentation at the 11th Annual SVB Leerink Global Healthcare Conference

WALTHAM, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TC...

7 months ago - GlobeNewsWire

FDA Gives Nod To TScan Therapeutics' Early-Stage Trial Of TSC-100 In Hematologic Malignancies

The FDA has signed off TScan Therapeutics Inc's (NASDAQ: TCRX) investigational new drug (IND) application for TSC-100 in hematologic malignancies patients undergoing allogeneic hematopoietic cell transp...

8 months ago - Benzinga

TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-100 for the Treatment of H...

– Phase 1 trial of TSC-100 expected to initiate in the first half of 2022 –

8 months ago - GlobeNewsWire

TScan Outlines 2022 Priorities as Programs Enter Clinic

IND Submissions Completed in Fourth Quarter 2021 for Lead Liquid Tumor TCR-T Candidates TSC-100 and TSC-101

8 months ago - GlobeNewsWire

TScan Therapeutics Announces Poster Presentations at the 63rd American Society of Hematology Annual Meeting and Expos...

-  Posters highlight discovery of TSC-101, manufacturing process and clinical development plan for liquid tumor candidates TSC-101 and TSC-102 -

9 months ago - GlobeNewsWire

TScan Therapeutics to Host a Virtual Event to Discuss Highlights from the 63rd ASH Annual Meeting and Exposition

- Event to feature Dr. Yi-Bin Chen, M.D., M.S., from MGH and Harvard Medical School - - Event to feature Dr. Yi-Bin Chen, M.D., M.S., from MGH and Harvard Medical School -

9 months ago - GlobeNewsWire

TScan Therapeutics Establishes Facility to Manufacture T Cell Receptor Engineered T Cell Therapies

- Completion of facility supports upcoming clinical milestones including expected multiple fourth quarter IND filings - - Completion of facility supports upcoming clinical milestones including expected ...

9 months ago - GlobeNewsWire

TScan Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress

IND Submissions Expected in Fourth Quarter 2021 for Lead Liquid Tumor TCR-T Therapy Candidates TSC-100 and TSC-101

10 months ago - GlobeNewsWire